Valve thrombosis and antithrombotic therapy after bioprosthetic mitral valve replacement: a systematic review and meta-analysis
European Heart Journal - Cardiovascular Pharmacotherapy · 02.05.2025 · 11 (3) · 251-263
DOI: 10.1093/ehjcvp/pvaf005 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, online erschienen am 04.02.2025. Verfasst von Mark J Zorman und 24 weiteren Autor:innen. Beteiligte Einrichtung: Oxford Heart Centre, Oxford University Hospitals NHS Trust, Headley Way, Oxford, OX3 9DU, UK. Hauptthemen laut MEDLINE: Bioprosthesis, Mitral Valve, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aims Transcatheter mitral valve replacement (TMVR) has become a feasible alternative to surgical mitral valve replacement (SMVR) in selected patients at high surgical risk. The risk of valve thrombosis following SMVR and TMVR, and the optimal antithrombotic therapy following these procedures, remains uncertain. We aimed to compare the incidence of bioprosthetic mitral valve thrombosis (bMVT) after SMVR and TMVR, and the incidence of bMVT between patients on different antithrombotic regimens. Methods and results A literature search of Medline, Embase, and Cochrane Library was performed between January 2000 and August 2024. Random-effects models were used to derive pooled estimates of the incidence of bMVT in the absence of prior or active endocarditis and valve thrombosis. A total of 47 studies (6170 patients, total follow-up 9541.8 patient-years) were eligible for inclusion. The overall incidence of bMVT was 5.05 [95% confidence interval (CI) 3.18–8.01, I2 = 82%] per 100-patient-years. Subclinical bMVT was more common than clinically significant bMVT: incidence 19.11 vs. 7.91 per 100-patient-years, adjusted incidence rate ratio (aIRR) 4.62 (95% CI 1.39–15.36), P = 0.012. bMVT was numerically more common after TMVR than SMVR, but the comparison was not statistically significant: incidence 7.03 vs. 0.58 per 100-patient-years, aIRR 2.19 (95% CI 0.72–6.72), P = 0.170. Patients on vitamin-K antagonists (VKA) had a lower incidence of bMVT than patients on direct oral anticoagulants (DOAC; incidence 5.72 vs. 17.08, aIRR 0.31, 95% CI 0.13–0.73, P = 0.007). Conclusions bMVT is not uncommon, with numerically higher incidence in transcatheter compared to surgical valves, but the comparison was not statistically significant. VKAs are associated with a lower incidence of bMVT compared to DOACs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oxford Heart Centre, Oxford University Hospitals NHS Trust, Headley Way, Oxford, OX3 9DU, UK.
- Department of Cardiovascular Medicine, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA.
- Health Care Libraries, University of Oxford, John Radcliffe Hospital, Headley Way, Oxford, OX3 9DU, UK.
- Nuffield Department of Primary Care Sciences, University of Oxford, Radcliffe Observatory Quarter, Woodstock Road, OX2 6GG, UK.
ORCID-Profile: Mark J Zorman, James Newton, Sam Dawkins, Mackram F Eleid, Sorin V Pislaru
Zitieren
APA
Zorman, M. J., Vibhishanan, J., Dangas, K., Castle, J., Li, K. H. C., Coronelli, M., Eastwick-Jones, K., Swan, A., Johnson, N., Choksey, A., Yan, H., Scott, S. G. C., Henry, M., Cassar, M. P., Barnes, C., Ferreira-Martins, J., Newton, J., Dawkins, S., Alkhouli, M., …, & Cahill, T. J. (2025). Valve thrombosis and antithrombotic therapy after bioprosthetic mitral valve replacement: a systematic review and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 11(3), 251-263. https://doi.org/10.1093/ehjcvp/pvaf005
Vancouver
Zorman MJ, Vibhishanan J, Dangas K, Castle J, Li KHC, Coronelli M, et al. Valve thrombosis and antithrombotic therapy after bioprosthetic mitral valve replacement: a systematic review and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy. 2025;11(3):251-263. doi:10.1093/ehjcvp/pvaf005
BibTeX
@article{Zorman2025,
author = {Zorman, Mark J and Vibhishanan, Jonathan and Dangas, Katerina and Castle, James and Li, Ka Hou Christien and Coronelli, Marco and Eastwick-Jones, Kate and Swan, Alexander and Johnson, Nicky and Choksey, Anurag and Yan, Helen and Scott, Sam G C and Henry, Matthew and Cassar, Mark Philip and Barnes, Cara and Ferreira-Martins, Joao and Newton, James and Dawkins, Sam and Alkhouli, Mohamad and Rihal, Charanjit and Eleid, Mackram F and Pislaru, Sorin V and Guerrero, Mayra E and Ordonez-Mena, Jose and Cahill, Thomas J},
title = {Valve thrombosis and antithrombotic therapy after bioprosthetic mitral valve replacement: a systematic review and meta-analysis},
journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
year = {2025},
volume = {11},
number = {3},
pages = {251--263},
doi = {10.1093/ehjcvp/pvaf005}
}
EUVIMED